INDIANAPOLIS, May 13, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved Cyramza (ramucirumab injection, 10 mg/mL solution), as a single agent, for the treatment of…Original Article
You may also like
FDA Approves Hympavzi (marstacimab-hncq) for the...
FDA Approves Itovebi (inavolisib) for the Combination...
U.S. Food and Drug Administration Approves...
FDA Approves Otulfi (ustekinumab-aauz), a Biosimilar...
Dupixent Approved in the US as the First-Ever Biologic...
FDA Approves Flyrcado (flurpiridaz F 18) Radioactive...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.